STRATA Skin Sciences Inc (SSKN) fair value: what the stock is really worth
We calculate from audited financials what STRATA Skin Sciences Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 29, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch STRATA Skin Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0001 – $19.30 · fair‑value band $0.0049 – $0.0054 · the $0.0050 price screens below the $0.0054 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 29, 2026.
Follow STRATA Skin Sciences in your weekly email
Every Wednesday you see whether STRATA Skin Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America.
Show more
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
Stock analysis
STRATA Skin Sciences Inc (SSKN) currently trades at $0.0050, while our model-based Fair Value estimate is $0.0054, implying the stock looks roughly 7.4% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0049 (bear) to $0.0054 (bull), the price of $0.0050 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
STRATA Skin Sciences Inc reported revenue of $30.7M in FY2025 versus $30.0M in FY2021, a compound +0.6%/yr. Reported net income was −$6.3M in FY2025.
Key figures
Market cap $707K · P/S ratio 0.02 · EPS (TTM) $−1.35 · Net margin −20.4% · Return on equity −159% · Return on assets (EBIT) −16.7% · Operating margin 0.4% · Revenue (TTM) $30.7M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 100% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 8%, SSKN screens cheaper than that median.
Fair Value models
Bear $0.0049Fair Value $0.0054Bull $0.0054
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.10/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Start year 2020 (pandemic). Over 10 years: +5.2% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.7% (2020) → −19.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare STRATA Skin Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside+8% · Above median
Profitability
Return on assets−11% · Bottom 25%
Net margin (TTM)−20% · Bottom 25%
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth−3% · Below median
Balance sheet
Debt / equity5.22× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.24× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is STRATA Skin Sciences Inc (SSKN) overvalued or undervalued?
As of Jul 29, 2026, our model estimates a fair value of $0.0054 versus the last price from Sep 18, 2026 of $0.0050, about +8% upside (fairly valued).
What is the fair value of SSKN?
Our model-based fair value for STRATA Skin Sciences Inc is $0.0054 (as of Jul 29, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.0050.
What is the quality score of SSKN?
STRATA Skin Sciences Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for STRATA Skin Sciences Inc (SSKN)?
Our model-based price target is the fair value of $0.0054 (as of Jul 29, 2026) from 1 valuation models. Cautious scenario $0.0049, optimistic scenario $0.0054. It is a calculation from audited fundamentals, not an analyst target.
What is the STRATA Skin Sciences Inc stock forecast for 2026?
Our models put fair value at $0.0054, about +8% upside versus the last price from Sep 18, 2026 of $0.0050 (fairly valued). Cautious scenario $0.0049, optimistic scenario $0.0054. The calculation is refreshed regularly with new filings.
What is the revenue of STRATA Skin Sciences Inc (SSKN)?
STRATA Skin Sciences Inc reported trailing-twelve-month revenue of about $30.7M (latest available figure, as of Jul 29, 2026).
What is the intrinsic value of STRATA Skin Sciences Inc (SSKN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For STRATA Skin Sciences Inc it is $0.0054 per share (as of Jul 29, 2026), against a price of $0.0050. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is STRATA Skin Sciences Inc stock overvalued or undervalued in 2026?
As of Jul 29, 2026, SSKN trades below its calculated fair value: price $0.0050, fair value $0.0054, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SSKN?
No. The price is what the market pays today ($0.0050); the fair value is what the company's own numbers justify ($0.0054). For STRATA Skin Sciences Inc the two are $0.0004 per share apart. That gap is exactly why we show both numbers side by side.
How much is STRATA Skin Sciences Inc worth?
The market values STRATA Skin Sciences Inc at about $707K (market capitalisation, as of Jul 29, 2026). Per share that is $0.0050; our models calculate a fair value of $0.0054 per share.
What do the bullish and bearish scenarios say about SSKN?
Our models span a range for STRATA Skin Sciences Inc: cautious scenario $0.0049, base $0.0054, optimistic $0.0054 per share (as of Jul 29, 2026, price $0.0050). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of SSKN?
The PEG ratio of STRATA Skin Sciences Inc is 0.03 (P/E divided by earnings growth, as of Jul 29, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of STRATA Skin Sciences Inc (SSKN)?
Balance-sheet figures for STRATA Skin Sciences Inc (as of Jul 29, 2026): return on equity −158.9%, debt of 5.22 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is SSKN from its 52-week high?
STRATA Skin Sciences Inc trades at $0.0050, about 100% below its 52-week high of $2.59 and at the low of $0.0050 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0054 is for.
Which stocks are comparable to STRATA Skin Sciences Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is STRATA Skin Sciences Inc stock attractive at the current price?
The data as of Jul 29, 2026: price $0.0050, calculated fair value $0.0054 (+8%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SSKN calculated?
We run STRATA Skin Sciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0054, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. STRATA Skin Sciences Inc currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of STRATA Skin Sciences Inc (SSKN)?
The latest price we hold is from Sep 18, 2026 and stands at $0.0050. Our model-based fair value is $0.0054, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with STRATA Skin Sciences Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0049 to $0.0054), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of STRATA Skin Sciences Inc
How large is the market capitalisation of STRATA Skin Sciences Inc (SSKN)?
The market capitalisation of STRATA Skin Sciences Inc is $707K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of STRATA Skin Sciences Inc (SSKN)?
The price-to-sales ratio of STRATA Skin Sciences Inc is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of STRATA Skin Sciences Inc (SSKN)?
Earnings per share at STRATA Skin Sciences Inc are $−1.35. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of STRATA Skin Sciences Inc (SSKN)?
The net margin of STRATA Skin Sciences Inc is −20.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of STRATA Skin Sciences Inc (SSKN)?
The return on equity (ROE) of STRATA Skin Sciences Inc is −159% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of STRATA Skin Sciences Inc (SSKN)?
On an EBIT basis the return on assets of STRATA Skin Sciences Inc is −16.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of STRATA Skin Sciences Inc (SSKN)?
The operating margin of STRATA Skin Sciences Inc is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at STRATA Skin Sciences Inc (SSKN)?
Revenue at STRATA Skin Sciences Inc is growing −3.0% versus a year earlier (3y avg −5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does STRATA Skin Sciences Inc (SSKN) generate?
The free cash flow of STRATA Skin Sciences Inc is −$4.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does STRATA Skin Sciences Inc (SSKN) carry?
The net debt of STRATA Skin Sciences Inc is $8.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch STRATA Skin Sciences Inc in the live analysis
One click puts STRATA Skin Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 29, 2026